Recent Research Analysts’ Ratings Changes for Zimmer Biomet (ZBH)

Several brokerages have updated their recommendations and price targets on shares of Zimmer Biomet (NYSE: ZBH) in the last few weeks:

• 10/15/2024 – Zimmer Biomet had its price target lowered by analysts at Oppenheimer Holdings Inc. from $145.00 to $135.00. They now have an “outperform” rating on the stock.
• 10/14/2024 – Zimmer Biomet had its price target lowered by analysts at Raymond James from $128.00 to $123.00. They now have an “outperform” rating on the stock.
• 10/8/2024 – Zimmer Biomet had its price target lowered by analysts at Royal Bank of Canada from $130.00 to $120.00. They now have an “outperform” rating on the stock.
• 10/3/2024 – Zimmer Biomet had its price target lowered by analysts at BTIG Research from $134.00 to $126.00. They now have a “buy” rating on the stock.
• 10/1/2024 – Zimmer Biomet had its price target lowered by analysts at Evercore ISI from $113.00 to $110.00. They now have an “in-line” rating on the stock.
• 9/17/2024 – Zimmer Biomet had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 9/16/2024 – Zimmer Biomet had its price target lowered by analysts at JPMorgan Chase & Co. from $125.00 to $120.00. They now have a “neutral” rating on the stock.
• 9/13/2024 – Zimmer Biomet had its “hold” rating reaffirmed by analysts at Truist Financial Co.. They now have a $112.00 price target on the stock, down previously from $117.00.
• 9/10/2024 – Zimmer Biomet is now covered by analysts at Wolfe Research. They set a “peer perform” rating on the stock.
• 9/10/2024 – Zimmer Biomet had its price target lowered by analysts at Canaccord Genuity Group Inc. from $120.00 to $115.00. They now have a “hold” rating on the stock.
• 9/6/2024 – Zimmer Biomet had its price target lowered by analysts at TD Cowen from $143.00 to $119.00. They now have a “hold” rating on the stock.
• 9/5/2024 – Zimmer Biomet had its “in-line” rating reaffirmed by analysts at Evercore ISI. They now have a $113.00 price target on the stock.
• 9/5/2024 – Zimmer Biomet had its “hold” rating reaffirmed by analysts at Truist Financial Co.. They now have a $117.00 price target on the stock.
• 8/20/2024 – Zimmer Biomet had its price target lowered by analysts at Canaccord Genuity Group Inc. from $130.00 to $120.00. They now have a “hold” rating on the stock.

Zimmer Biomet Stock Up 0.8 %

Shares of NYSE:ZBH opened at $105.45 on Thursday. The stock has a market cap of $21.69 billion, a price-to-earnings ratio of 22.82, a PEG ratio of 1.93 and a beta of 1.02. The company has a quick ratio of 0.63, a current ratio of 1.29 and a debt-to-equity ratio of 0.31. Zimmer Biomet Holdings, Inc. has a 12-month low of $101.47 and a 12-month high of $133.90. The business’s 50 day moving average is $108.22 and its 200 day moving average is $112.64.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.02. Zimmer Biomet had a return on equity of 12.86% and a net margin of 13.25%. The company had revenue of $1.94 billion for the quarter, compared to analysts’ expectations of $1.94 billion. During the same quarter in the previous year, the firm earned $1.82 earnings per share. Zimmer Biomet’s quarterly revenue was up 3.9% on a year-over-year basis. On average, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.98 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be given a $0.24 dividend. The ex-dividend date of this dividend is Monday, September 30th. This represents a $0.96 annualized dividend and a yield of 0.91%. Zimmer Biomet’s dividend payout ratio is currently 20.78%.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ZBH. Wellington Management Group LLP purchased a new position in shares of Zimmer Biomet during the 4th quarter valued at $1,335,000. SageView Advisory Group LLC purchased a new position in shares of Zimmer Biomet during the 4th quarter valued at $321,000. B. Riley Wealth Advisors Inc. lifted its position in shares of Zimmer Biomet by 4.3% during the 4th quarter. B. Riley Wealth Advisors Inc. now owns 3,414 shares of the medical equipment provider’s stock valued at $416,000 after buying an additional 141 shares during the last quarter. HighPoint Advisor Group LLC bought a new stake in shares of Zimmer Biomet during the 4th quarter valued at $297,000. Finally, Nomura Holdings Inc. bought a new stake in shares of Zimmer Biomet during the 4th quarter valued at $513,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.